We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

FUJIREBIO

Fujirebio is a global leader in the field of IVD testing with more than 50 years’ experience in the conception, devel... read more Featured Products: More products

Download Mobile App




Fujirebio and Sysmex Collaborate for Development and Advancement of Immunoassay

By LabMedica International staff writers
Posted on 18 Dec 2023
Print article
Image: Fujirebio and Sysmex have signed an agreement for the supply of reagent raw materials in the field of immunoassay (Photo courtesy of 123RF)
Image: Fujirebio and Sysmex have signed an agreement for the supply of reagent raw materials in the field of immunoassay (Photo courtesy of 123RF)

Fujirebio Holdings (Tokyo, Japan) and Sysmex Corporation (Kobe, Japan) have signed an agreement for the mutual supply of reagent raw materials owned by both companies. The agreement is based on a basic agreement on business collaboration in the field of immunoassay signed by the two companies in October 2023.

In October 2023, Fujirebio and Sysmex entered into a basic agreement on business collaboration in the field of immunoassay, intending to promote cooperation to accelerate their global expansion, and to contribute to the development and advancement of immunoassay. To promote specific initiatives, the two companies signed a Contract Development and Manufacturing Organization (CDMO) agreement in November 2023 related to dedicated reagents for the HISCL-Series automated immunoassay system, involving the development of reagents for cerebral-spinal fluid-based and blood-based testing in the field of neurodegenerative diseases, including Alzheimer’s disease.

As per the terms of the agreement, Fujirebio and Sysmex will mutually supply a wide range of reagent materials owned by each company, primarily antigens and antibodies, which are the key raw materials of immunoassay reagents. This will allow the CDMO to speed up reagent development, lower costs, and maximize the value of raw material assets while building a stable supply system to meet the global demand growth in the future and prepare for raw material procurement risk in case of an emergency. By strengthening cooperation in the area of reagent materials, Fujirebio and Sysmex will promote the mutual utilization of their high-quality reagent materials. Additionally, they will continue to work together in the future to develop new parameters and technologies.

Related Links:
Fujirebio Holdings
Sysmex Corporation

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Researchers have found a way to spot the debilitating disease Alzheimer\'s before it develops into dementia (Photo courtesy of 123RF)

Advanced Blood Test to Spot Alzheimer's Before Progression to Dementia

Alzheimer’s disease is well known for its slow development over many years, which typically leads to treatment interventions only after the disease has advanced to stages where it may be nearly impossible... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new method is quick and easy, and can also be used by non-medical personnel. (Photo courtesy of Zoratto et al. Advanced Science 2024, edited)

New Blood Test Device Modeled on Leeches to Help Diagnose Malaria

Many individuals have a fear of needles, making the experience of having blood drawn from their arm particularly distressing. An alternative method involves taking blood from the fingertip or earlobe,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.